This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technologyinnovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.
The Heart Rhythm Society (HRS) is preparing for HRX 2024, the third annual event of its kind, which will be held from September 5-7, 2024, in Atlanta, GA, gathering cardiovascular health innovators together to explore discoveries and advance partnerships between medicine and technology. On Thursday, Sept.
milla1cf Wed, 02/07/2024 - 18:05 February 7, 2024 — The Consumer Technology Association ( CTA ) and the American College of Cardiology ( ACC ) are announcing the release of their second industry framework for the use of consumer cardiovascular technology solutions in the screening and diagnosis for cardiovascular conditions.
An international consensus statement on how to treat atrialfibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November. This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
milla1cf Fri, 02/02/2024 - 17:18 February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. million people in the United States by 2050 and 17.9 million in Europe by 2060.
28, 2025 At theAmerican College of Cardiology (ACC) 2025 meeting,GE HealthCare will introduce RevolutionVibe, i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrialfibrillation and heavily calcified coronaries.
cardiac electrophysiologist, performed one of the nations first procedures to control atrialfibrillation (Afib) using a new type of catheter that can deliver two different types of electrical energy or ablation to destroy the damaged part of the heart that is triggering the abnormal heartbeats. 12, 2025 On Feb.
Clinical trials and innovativetechnology took center stage during the month of April, racking up some record number views. New Study Reveals 65 and Older Population Lowered Blood Pressure, Cholesterol and Weight Using Mobile Technology 2. Shorten the Blanking Period After AtrialFibrillation Ablation, Experts Say 4.
mtaschetta-millane Tue, 07/16/2024 - 09:47 July 16, 2024 — Ultrahuman, a pioneer in wearable technology , launches PowerPlugs, a platform for individual apps and plugins built on top of Ultrahuman’s health and wellness data stack. UltraSignal will help fuel more customization and innovation in health.
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrialfibrillation (NVAF) treatment. It's exciting to be part of the evolution of the latest technology into a tangible solution for treating patients. Jennifer Currin, Ph.D.,
In the age of technology, wearable devices have revolutionized how we approach health and wellness. This blog explores the ways wearable technology can help track heart health, the advantages it offers, and how it contributes to better outcomes for those requiring surgical intervention.
tim.hodson Mon, 03/31/2025 - 15:02 March 31, 2025 iRhythm Technologies, Inc. AF Often Asymptomatic: Even for atrialfibrillation (AF)the most commonly symptomatic arrhythmiaover half of all cases were asymptomatic. Its estimated that undiagnosed atrialfibrillation alone costs the U.S. $3 2016;11(8).
With the integration of Osso VR's immersive technology and the expertise of the ACC, interventionalists will gain access to a state-of-the-art training simulation of the workflow and skills required to successfully perform a left atrial appendage occlusion procedure (LAAO). and globally."
BackgroundCatheter ablation is frequently used to manage recurrent atrialfibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).
Pulsed field ablation (PFA) is an innovativetechnology recently adopted for treating atrialfibrillation (AF). Preclinical and clinical studies have reported a reassuring safety profile because of its tissue-specific effect, sparing adjacent tissues.1
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation [abstract].
Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will have access to real-time, step-by-step guidance to capture diagnostic-quality images and automated ejection fraction estimation to help inform clinical decisions across cardiac settings. Of these, approximately 30 are AI-enabled ultrasound innovations.
With the rise of digital health, innovative solutions are emerging that can significantly impact patient care and recovery while simultaneously addressing health equity. Technology tools are becoming more sophisticated, bidirectional and disease-specific, and are being designed with home care in mind.
These measurements can enable the early detection and monitoring of heart rhythm conditions such as atrialfibrillation. This makes FibriCheck the only smartphone application using PPG-technology that is FDA-cleared with equivalence to ECG. The FDA-clearance also allows FibriCheck to improve current U.S.
With these innovations, we’re not just delivering advanced technology; we’re offering practical solutions that have a real impact on both clinicians and patients, ensuring healthcare delivery is both effective and compassionate in today’s demanding environment,” said Taha Kass-Hout , MD, MS, Chief Technology and Science Officer, GE HealthCare.
a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrialfibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrialfibrillation ( AF ) using pulsed field ablation (PFA). AtrialFibrillation. Circulation.
It further reported that MHIF led the way as the first to provide this technology to a patient as part of an early research study in 2017 and completed the first-in-the-world enrollment in the pivotal trial in August 2019. When left untreated, TR can lead to atrialfibrillation, heart failure, and ultimately, death.
Over the past 3 days cardiologists from all over the world met in New Orleans to learn and discuss the developments in technology and patient care. As ECG Excellence we are proud our CineECG technology was part of this innovation festival. Their study focuses on the issue of localizing the origin of atrial ectopic activity.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 AtrialFibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
4 Conditions such as Ischemic Heart Disease, AtrialFibrillation, Hypertensive Heart Disease, and Ischemic Stroke make up almost 75% of the deaths due to cardiovascular disease. Specialists need to partner with local primary care clinicians – using technology to meet patients where they are – to reverse this reality.
OSA is commonly seen in patients with arrhythmias like atrialfibrillation (AFib) and due to the variable unpredictable nature of sleep apnea symptoms, it is often untreated, leading to adverse outcomes. Peerbridge Health continues to innovate by compounding clinical utility in one simple device," said Andrea Natale, M.D.,
About a million possible cases of atrialfibrillation, a known risk for stroke, go undetected in Japan. A local startup is introducing an innovative AI targeting this growing danger. Where are you now in this process and what can you tell us about this technology and the problem it seeks to solve?
Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases. Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc.
With this approval, Medtronic now offers two PFA technologies available for patients with Afib. We will continue to fulfill our commitment to innovation, including new indications, to advance cardiovascular care and improve patient outcomes." tim.hodson Wed, 10/30/2024 - 13:42 Oct. The potential of Affera is limitless.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content